Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to find pancreatic cancer early, specifically in patients who have certain types of pancreatic cysts that may be at high risk. Researchers believe that using a combination of advanced imaging techniques, including a special type of MRI scan and a unique PET scan, along with blood tests, could help detect pancreatic ductal adenocarcinoma (PDAC) before it becomes a serious problem. By catching it early, the goal is to reduce the need for more invasive procedures like surgery.

To participate in this study, you need to be an adult over 18 years old with a specific type of pancreatic cyst that requires surgery. However, if you have been diagnosed with pancreatic cancer, are pregnant or breastfeeding, or have certain health issues that might prevent you from undergoing the scans, you won't be able to take part. If you join the trial, you can expect to undergo these imaging tests and blood tests, which will help researchers learn more about how to detect pancreatic cancer early and improve outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women aged \>18 years
• • Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
• • Able to provide informed consent
• Exclusion Criteria:
• • Pathologic evidence of pancreatic cancer
• • Pregnant or breast-feeding patients
• • Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
• • Inability to lay flat or meet the standard requirements of traditional MRI
• • Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
• • 1. Bilirubin \> 1.5 x ULN
• • 2. AST/ALT \> 2.5 x ULN
• • 3. Albumin \< 3 g/dL
• • 4. GGT \> 2.5 x ULN if Alkaline Phosphatase \> 2.5 x ULN
• • Renal function with Creatinine \> 1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
• • Cardiac: congestive heart failure with New York Heart Association (NYHA) status ≥2, poorly controlled hypertension, a history of clinically significant EKG abnormalities, or myocardial infarction within 6 months of study enrollment.